Does intermittent fasting really beat standard dieting? What the Cochrane review found

Does intermittent fasting do more for weight loss than ordinary dieting? A new 2026 Cochrane review suggests probably not. Across the trials it assessed, fasting did little to pull ahead of standard dietary advice, and the underlying evidence was mostly short term.

The ScienceDaily summary of the review turned that into a clean headline. The paper itself is more guarded, which is the more useful reading.

In this research, intermittent fasting means planned stretches of little or no energy intake. Standard dieting usually means regular dietary advice or continuous energy restriction: an ordinary daily calorie deficit rather than a narrow eating window. Garegnani and colleagues were not arguing that fasting can never help. Their point was narrower. In adults with overweight or obesity, fasting has not clearly beaten ordinary calorie-cutting advice.

Marketing often treats fasting as metabolically special. Readers usually want a simpler answer: if two people are eating less overall, does meal timing add much on top? The Cochrane review suggests any extra benefit has been hard to show.

What the Cochrane review actually compared

Here the numbers matter. The review by Luis I Garegnani and colleagues in Cochrane Database of Systematic Reviews pooled 22 randomized controlled trials with 1,995 participants. Most studies enrolled adults with overweight or obesity. Some compared intermittent fasting with regular dietary advice. Others compared fasting with no intervention.

Cochrane’s plain-language summary put the topline this way:

“Compared to traditional dietary advice … intermittent fasting may make little to no difference to weight loss and quality of life.”

Cochrane plain-language summary

Readers can still overread that line. Intermittent fasting is an umbrella label that covers alternate-day fasting, whole-day fasting on selected days, and time-restricted eating. What the review found was more limited: when those approaches were tested against ordinary dietary advice, the average advantage for fasting was small.

Minus 0.33 percentage points was the key estimate for weight loss from baseline versus dietary advice. In practice, that is not much daylight. Anyone expecting a decisive fasting advantage will not find it in this paper.

Why the evidence is less decisive than the headlines suggest

Caution is part of the result here. Garegnani and colleagues said the evidence was low certainty and mostly short term. In systematic-review language, that means the conclusion could move if better trials arrive.

Again, the authors were direct in the PubMed summary of the review:

“These approaches did not differ in achieving weight loss, producing no clinically meaningful changes in most of the outcomes considered in this review.”

Cochrane authors

Several limits explain the restraint. Many trials were brief. Some patient-relevant outcomes, including treatment satisfaction and diabetes status, were missing or unevenly reported. Weight loss is also a noisy endpoint; adherence, dropout, baseline diet quality, and medication use can all shift it. A diet that looks tidy in a protocol may work very differently in an actual kitchen.

“Little or no difference” is therefore more informative than “fasting doesn’t work.” Cochrane compared fasting with another active strategy, not with doing nothing. Structured diets of several kinds can produce short-term weight loss. The harder question is whether one approach reliably beats another once support, follow-up, and total energy intake are taken seriously.

Why the fasting debate keeps coming back

One reason the debate keeps returning is that fasting protocols are not interchangeable, and the rest of the literature does not line up perfectly. A 2025 BMJ network meta-analysis by Zhila Semnani-Azad and colleagues looked across 99 randomized clinical trials and found that both intermittent fasting and continuous energy restriction reduced body weight compared with eating without restriction.

BMJ’s review also found a small short-term advantage for alternate-day fasting over continuous energy restriction, about 1.29 kilograms in some comparisons. That does not cancel out the Cochrane review. It helps explain why the subject keeps resurfacing. Different reviews ask different questions, group fasting subtypes in different ways, and give short trials different weight.

Adherence may be the less glamorous but more important explanation. Some people find a time-restricted pattern easier than counting calories every day. Others struggle with fasting windows and compensate later. If trials do not sort out those practical differences, competing diet strategies can end up looking closer than their advocates suggest.

Clinicians and readers can take a modest conclusion from that. Intermittent fasting is not disproven. It is just not clearly superior on the best short-term evidence available now. That is a smaller claim than the marketing pitch, but it is also easier to defend.

What readers should watch next

Longer trials will matter more than louder headlines. The next useful studies need to separate time-restricted eating from alternate-day fasting, track adherence carefully, and report more than body weight. Quality of life, metabolic markers, medication use, and whether people can live with the plan over time matter at least as much as the number on the scale.

For now, the Cochrane review works best as a check on the hype. The central question was never whether a structured eating plan can help some people eat less. It was whether intermittent fasting clearly beats standard dieting. On current evidence, it does not.

References

1. Garegnani LI, Oltra G, Ivaldi D, et al. Intermittent fasting for adults with overweight or obesity. Cochrane Database Syst Rev. 2026. https://pubmed.ncbi.nlm.nih.gov/41692034/
2. Semnani-Azad Z, Khan TA, Chiavaroli L, et al. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12175170/